Discounted Cash Flow
Takeda Pharmaceutical Co. Ltd. ADR
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2017 | $1.7t | $143.3b | $261.4b | 8.3% | $147.15 |
| 2018 | $1.8t (2.2%) | $217.2b (51.5%) | $377.9b (44.6%) | 12.3% (48.2%) | $239.35 (62.7%) |
| 2019 | $2.1t (18.5%) | $109.1b (-49.8%) | $327.3b (-13.4%) | 5.2% (-57.6%) | $113.50 (-52.6%) |
| 2020 | $3.3t (56.9%) | $44.2b (-59.5%) | $44.2b (-86.5%) | 1.3% (-74.2%) | $28.41 (-75.0%) |
| 2021 | $3.2t (-2.8%) | $376.0b (749.9%) | $1.0t (2180.2%) | 11.8% (774.7%) | $240.72 (747.3%) |
| 2022 | $3.6t (11.6%) | $230.1b (-38.8%) | $1.0t (3.6%) | 6.4% (-45.2%) | $147.14 (-38.9%) |
| 2023 | $4.0t (12.8%) | $317.0b (37.8%) | $950.2b (-9.1%) | 7.9% (22.1%) | $204.29 (38.8%) |
| 2024 | $4.3t (5.9%) | $144.1b (-54.6%) | $714.0b (-24.9%) | 3.4% (-57.1%) | $92.09 (-54.9%) |
| 2025 | $4.6t (7.5%) | $107.9b (-25.1%) | $1.0t (40.8%) | 2.4% (-30.3%) | $68.36 (-25.8%) |
| 2026 | $4.5t (-1.7%) | $-142.4b (-231.9%) | $626.8b (-37.7%) | -3.2% (-234.1%) | $-96.75 (-241.5%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Values abbreviated: b = billions, m = millions, k = thousands.
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.